About IncellDx
IncellDx is a company based in Menlo Park (United States) founded in 2009. IncellDx has raised $9.5 million across 3 funding rounds from investors including Bioreference. IncellDx offers products and services including HPV E6, E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, in cellPREP Homogenizer, and Anti PD-L1 Antibody. IncellDx operates in a competitive market with competitors including BioLife Solutions, Sino Biological, GenScript, OncoDNA and Fluent BioSciences, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.5 M (USD)
in 3 rounds
-
Latest Funding Round
$500 K (USD), Series B
Jul 16, 2024
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IncellDx
IncellDx offers a comprehensive portfolio of products and services, including HPV E6, E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, in cellPREP Homogenizer, and Anti PD-L1 Antibody.
Detects HPV mRNA for cell analysis applications.
Identifies CMV mRNA in single cells.
Supports multiplex RNA detection processes.
Prepares tissue for single cell suspension.
Detects PD-L1 protein in cells.
People of IncellDx
Unlock access to complete
Funding Insights of IncellDx
IncellDx has successfully raised a total of $9.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $500 thousand completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IncellDx
IncellDx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bioreference.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pathology laboratory services are operated through a nationwide chain.
|
Locked | Locked | Locked |
Investor details for IncellDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IncellDx
Investment portfolio details for IncellDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IncellDx
Detailed financials for IncellDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Incelldx Comparisons
Peer comparison for IncellDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IncellDx
IncellDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioLife Solutions, Sino Biological, GenScript, OncoDNA and Fluent BioSciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Proprietary reagents for single-cell genetic analysis are developed.
|
|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
Detailed competitors of IncellDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Incelldx
Complete news archive for IncellDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IncellDx
IncellDx was founded in 2009 and raised its 1st funding round 1 year after it was founded.
IncellDx is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
IncellDx is a funded company, having raised a total of $9.5M across 3 funding rounds to date.
IncellDx was founded in 2009 and is headquartered in Menlo Park, United States. Molecular diagnostic assays and kits targeting infectious diseases such as human papillomavirus (HPV), cytomegalovirus (CMV), and HIV are developed and marketed. Consumables supporting flow cytometry applications are also offered. Operations focus on the diagnostics sector, providing tools for clinical and research use in infectious disease detection.
IncellDx's top competitors include Sino Biological, OncoDNA and BioLife Solutions.
IncellDx offers HPV E6, E7 mRNA Probe, CMV mRNA Probe, Hybridization Core Reagents, in cellPREP Homogenizer, and Anti PD-L1 Antibody.
IncellDx has 1 investor. Key investors include Bioreference.